Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia

Acute myeloid leukemia (AML) is the most common adult acute leukemia with 21,380 estimated new cases and 10,590 estimated deaths in 2017 [1]. For newly diagnosed AML patients, less than 60 years old, induction chemotherapy with infusional standard-dose cytarabine for 7  days plus an anthracycline (either idarubicin or daunorubicin) for 3 days is a National Comprehensive Cancer Network (NCCN) category 1 recommendation and is the standard of care for the last 30 years [2]. Memorial Sloan Kettering Cancer Center uses either idarubicin (IDA) or daunorubicin for th e treatment of AML, the doses of daunorubicin are either 60 mg/m2 (DNA60) or 90 mg/m2 (DNA90).
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research